Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.61 |
| ▸ | HTR2A | P28223 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 5/20 | 0.48 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14586632 | 0.90 | SLC6A4 (0.54) | SLC6A4HTR2AKCNH2L3MBTL1RAB9A | |
| SCHEMBL10001987 | 0.88 | AR (0.51) | SLC6A4HTR2AKCNH2L3MBTL1RAB9A | |
| SCHEMBL13997373 | 0.86 | SLC6A4 (0.64) | SLC6A4HTR2AKCNH2L3MBTL1RAB9A | |
| SCHEMBL10001973 | 0.86 | AR (0.51) | SLC6A4HTR2AKCNH2L3MBTL1RAB9A | |
| SCHEMBL15385015 | 0.83 | SLC6A4 (0.61) | SLC6A4HTR2AKCNH2L3MBTL1RAB9A | |
| SCHEMBL2786289 | 0.83 | AR (0.53) | SLC6A4HTR2AKCNH2L3MBTL1RAB9A | |
| SCHEMBL10001970 | 0.83 | SLC6A4 (0.47) | SLC6A4HTR2AKCNH2L3MBTL1RAB9A | |
| SCHEMBL3281979 | 0.82 | L3MBTL1 (0.77) | SLC6A4HTR2AKCNH2L3MBTL1RAB9A | |
| SCHEMBL15384989 | 0.82 | HTR2A (0.59) | SLC6A4HTR2AKCNH2L3MBTL1RAB9A | |
| SCHEMBL5583700 | 0.82 | TEAD4 (0.52) | SLC6A4HTR2AKCNH2L3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009111501-A1 | DERIVATIVES OF IMIDAZO [4, 5-D] PYRIDAZINE AND THEIR USE AS ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | MAVS, SARS1, HAVCR2 | SLC6A4 2574/4885HTR2A 4665/4885KCNH2 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.